Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK2 | Q13002 | 4/20 | 0.65 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21735535 | 0.91 | GRIK2 (0.79) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL11658854 | 0.86 | GRIK2 (0.72) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL10793249 | 0.79 | MTNR1A (0.52) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8642549 | 0.79 | GRIK2 (1.00) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL12352758 | 0.79 | NPSR1 (0.64) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL10793754 | 0.79 | CA2 (0.53) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL21735538 | 0.76 | MTNR1A (0.64) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL21735533 | 0.76 | GRIK1 (0.58) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL26292352 | 0.76 | GRIK2 (0.58) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL21335565 | 0.75 | NPSR1 (0.59) | GRIK2GRIK1SMN1; SMN2MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6221838-B1 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
| US-6124311-A | ADMINISTERING ONCOLYTIC AGENT WITH ENHANCED MULTIDRUG RESISTANCE REVERSING AMOUNT OF SPECIFIED COMPOUND | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6121292-A | BY ADMINSTERING A SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE, INDOLE, OR (DIHYDRO)NAPHTHYLENE, OF GIVEN FORMULA SUCH AS (6-(N-BUTYLSULFONOYL)-2-(4(N-BUTYLSULFONYL)PHENYL)BENZO(B)-THIEN-3-YL)(4(2 -(1-PIPERIDINYL)ETHOXY)PHENYL)METHANONE | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| US-5972888-A | LOWERING THE PRODUCTION OR RELEASE OF NEUROPEPTIDE Y WHICH COMPRISES ADMINISTERING TO A MAMMAL IN NEED THEREOF AN EFFECTIVE AMOUNT OF AN ISOLATED NATURALLY OCCURRING OBESITY PROTEIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ELI LILLY AND COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0895781-A2 | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0820769-A2 | Use of benzothiophenes for the manufacture of a medicament for the treatment of diseases associated with an excess of tachykinis | ELI LILLY AND COMPANY (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5663192-A | PSYCHOLOGICAL DISORDERS USING INDOLE, BENZOTHIOPHENE OR BENZOFURANS WITH AMINO AND ALKOXYBENZOYL GROUPS | ELI LILLY AND COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0759441-A2 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0754464-A2 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY (US) | 1997-01-22 | — | — | EP | disclosed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |